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Abstract
Background: The ability to regulate transgene expression has many applications, mostly concerning the
analysis of gene function. Desirable induction characteristics, such as low un-induced expression, high
induced expression and limited cellular heterogeneity, can be seriously impaired by chromosomal position
effects at the site of transgene integration. Many clones may therefore need to be screened before one
with optimal induction characteristics is identified. Furthermore, such screens must be repeated for each
new transgene investigated, and comparisons between clones with different transgenes is complicated by
their different integration sites.
Results: To circumvent these problems we have developed a "screen and insert" strategy in which clones
carrying a transgene for a fluorescent reporter are first screened for those with optimal induction
characteristics. Site-specific recombination (SSR) is then be used repeatedly to insert any new transgene
at the reporter transgene locus of such clones so that optimal induction characteristics are conferred upon
it. Here we have tested in a human fibrosarcoma cell line (HT1080) two of many possible implementations
of this approach. Clones (e.g. Rht14-10) in which a GFP reporter gene is very stringently regulated by the
tetracycline (tet) transactivator (tTA) protein were first identified flow-cytometrically. Transgenes
encoding luciferase, I-SceI endonuclease or Rad52 were then inserted by SSR at a LoxP site adjacent to the
GFP gene resulting stringent tet-regulated transgene expression. In clone Rht14-10, increases in
expression from essentially background levels (+tet) to more than 104-fold above background (-tet) were
reproducibly detected after Cre-mediated insertion of either the luciferase or the I-SceI transgenes.
Conclusion: Although previous methods have made use of SSR to integrate transgenes at defined sites,
none has effectively combined this with a pre-selection step to identify integration sites that support
optimal regulatory characteristics. Rht14-10 and similar HT1080-derived clones can now be used in
conjunction with a convenient delivery vector (pIN2-neoMCS), in a simple 3-step protocol leading to
stringent and reproducible transgene regulation. This approach will be particularly useful for transgenes
whose products are very active at low concentrations and/or for comparisons of multiple related
transgenes.
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Background
The introduction of gene expression vectors into verte-
brate cells is a powerful way to investigate gene function.
Following transgene integration into the genome of a
recipient cell, stable, heritable phenotypes are studied in
cultured cells, or (if host cells are totipotent) in a develop-
ing/adult animal. Transgenes are typically used either to
express or down-regulate a specific target gene, the latter
being achieved via the use of RNA interference (RNAi) or
site-specific recombinases (e.g. Cre) whose recognition
sequences (e.g. loxP) have been engineered into the target
gene. In cases where the gain or loss of gene function
places host cells at a selective disadvantage, is lethal, or
has different consequences at different developmental
stages, temporally and/or spatially regulated transgene
expression is necessary [1-4].
Temporally regulated transgene expression can be
achieved with a variety of regulatory systems, but the most
widely used are based on the tetracycline (tet) repressor
TetR. The original Tet-Off system [5] is based on the tet-
transactivator (tTA), a fusion protein between TetR and a
minimal transactivation domain of the viral VP16 pro-
tein. In the absence of tet, tTA binds to tetO recognition
sequences in the Tet Response Element (TRE) upstream of
the gene to be regulated, and activates RNA polymerase II-
dependent transcription from an adjacent minimal pro-
moter (CMVmin). When tet is present, tTA dissociates
from the TRE and transcription ceases. Many variations on
the Tet-Off system have been developed (e.g. see [6-8])
often with the aim of improving stringency. A stringent
system here refers to one with minimal transgene expres-
sion before induction and robust expression after induc-
tion.
Use of tet-regulated transgenes either to express or silence
a target gene is already widespread in both cell lines and
animals, but new applications continue to be developed.
For example, with the growing use of site-specific recom-
binases [9,10], RNA polymerase II-based methods for sta-
bly expressing short hairpin RNA (shRNA [11,12]), and
the expression of inducible transgenes in host cells with
disrupted target alleles [13,14], the scope for tet-regulated
gene silencing is still expanding. While good stringencies
are often described in such studies, these can be time-con-
suming to generate and, depending on the purpose of the
study, may be less than ideal.
Chromosomal position effects [15] at the site of transgene
integration are key variables in the success of these
approaches as they can adversely affect the stringency of
tet-regulation. As a direct result, position effects increase
the effort required to identify cell or animal lines with suf-
ficiently stringent transgene regulation, and complicate
the comparisons between different lines. When evaluating
lines expressing two related inducible transgenes, for
example, any phenotypic variations can reflect differences
either between the protein products of the transgenes or,
more trivially, between their induced expression levels, as
determined by the transgene integration sites. Dissimilar
phenotypes can also indicate dysregulation of different
host genes close to the transgene integration sites [16].
To date, the influence of position effects on tet-regulation
has been limited in two different ways. One method uses
insulator sequences [17] to protect the transgene from sur-
rounding sequences (and vice versa). While this has been
useful in increasing stringency [18], variation between dif-
ferent clones remains. In another approach, site-specific
recombination (SSR) is used to integrate tet-regulated
transgenes at specific chromosomal loci [19-22]. This
approach effectively eliminates variations between clones,
allowing for reproducible induction characteristics, but its
success in improving stringency depends on the chosen
integration site and this has not been systematically opti-
mised.
Here we describe a new approach in which clones with
optimal integration sites are first identified by flow cyto-
metric screens of cells that have been stably transfected
with a loxP-tagged reporter transgene (encoding enhanced
green fluorescent protein [EGFP]). Cre-mediated recom-
bination is then used to insert a promoterless gene of
interest (GOI) at the loxP site of such clones. We have val-
idated this approach, which we term "Screen and Insert'
(or ScIn), using luciferase as a test GOI and two different
implementation strategies. We have also used the method
to generate clones that stringently regulate the expression
of I-SceI, an endonuclease widely used to study cellular
responses to the formation of DNA double strand breaks
(DSBs) [23,24], and Rad52, a protein involved in the
repair of DSBs by homologous recombination [25].
Results
Screen and insert: principles and implementation 
strategies
An outline of the basic Screen and Insert approach is
shown in Fig. 1A. A target construct is made in which a
reporter gene (EGFP) is expressed from a tet-responsive
promoter (TRP = TRE + CMVmin) with a loxP site posi-
tioned between the TRP and the reporter gene. Stably
transfected clones, each with the target construct ran-
domly integrated at a different site, are screened by flow
cytometry to identify those with stringently tet-regulated
EGFP expression. A chosen clone is then co-transfected
with a Cre-expression plasmid and an insertion construct
in which a promoterless GOI cassette is linked to a loxP
site. Cre-mediated recombination between the insertion
construct and the integrated target construct places the
GOI under the control of the TRP in the chosen clone.BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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Correct insertion events generate clones with stringently
tet-regulated GOI and no GFP expression.
In the present study we have tested two of many possible
ways in which the basic ScIn strategy can be implemented.
We will refer to these as ScIn-1 and ScIn-2 and their key
features are summarised in Fig. 1B and 1C, respectively.
The target construct (pTARG4) used for both ScIn-1 and
ScIn-2 carries a destabilised EGFP reporter gene (d2EGFP)
driven by an optimised TRP (from pTRE-tight, Clontech).
Positioned between the TRP and d2EGFP are a recogni-
tion site (FRT) for the Flp site-specific recombinase, and a
mutant loxP site, lox71. The FRT site is necessary for ScIn-
2 only. Lox71 was chosen because it is known to undergo
unidirectional Cre-dependent recombination with lox66
[26]. Thus, by use of a lox66 site in the insertion construct,
unimolecular Cre-mediated excision events that reverse
the desired integration events, are minimised.
Screen and Insert principles and strategies Figure 1
Screen and Insert principles and strategies. Configurations of plasmid DNA before and after its incorporation into 
genomic DNA are shown schematically (not to scale). A) Principles of the Screen and Insert approach. B) The Screen and 
Insert type 1 (ScIn-1) strategy. C) The Screen and Insert type 2 (ScIn-2) strategy. Promoterless cassettes are shown for a 
generic gene of interest (GOI), and for genes encoding green fluorescent proteins (EGFP and d2EGFP), luciferase (luc), hygro-
mycin phophotransferase (hygro) and guanosine phospribosyltranferase (gpt). See text for details.BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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In ScIn-1, the GOI (e.g. luciferase) is linked to a promot-
erless drug resistance marker gene (e.g. hyg) by an internal
ribosome entry site (IRES). With this arrangement it is
possible to select in drug (hygromycin) for the desired
insertion events. A limitation of ScIn-1 is that for drug
selection to work the GOI must also be expressed. In ScIn-
2 this limitation is avoided by use of an insertion con-
struct in which a promoterless drug-resistance gene (e.g.
gpt) is linked to the GOI (luciferase) by an FRT site. This
arrangement allows insertion events to be selected in drug
(Mycophenolic acid and xanthine [MPA/X]) without any
accompanying GOI expression. Efficient Flp-mediated
excision is then used to delete the drug-resistance marker
and bring the GOI under the control of the TRP, in the
presence of tet.
Screening: identification of clones with stringently 
regulated target constructs
Target constructs (Fig. 2A) were introduced into host cells
by co-electroporation with a plasmid (pBLpuroR) confer-
ring resistance to Puromycin (see methods). Two HT1080
(human fibrosarcoma) derivatives were used as host cells:
HT2 [27], which expresses the original tTA protein, or
Rht14 (see Methods) which expresses itTA [28], an
improved tTA whose gene is modified to eliminate CpG
dinucleotides and potential splice sites from the prokary-
otic coding DNA and to introduce eukaryotic codon-
usage. HT2 cells were used as a recipient for all target con-
structs except pTARG4, for which Rht14 was used. Most
(>70%) of puromycin-resistant (puror) colonies
expressed GFP as judged by fluorescence microscopy.
These were expanded and tested flow cytometrically for
tet-regulated GFP expression (methods). We sought to
identify clones with: i) high GFP expression in the absence
of tet, ii) low GFP in the presence of tet (as close as possi-
ble to the background fluorescence measured in untrans-
fected parental cells), and iii) 'single peak' profiles, i.e.
uniform expression throughout the population, whether
in the presence or the absence of tet.
An initial target construct (pTARG1) used the original TRE
[29]. Of over 100 puror  pTARG1 transfectants, many
showed good regulation, but even the best expressed sig-
nificant uninduced levels of GFP and required 144 h for
full down-regulation (e.g. clone 6, Fig. 2B). To facilitate
screening we used a second target construct (pTARG2)
with d2EGFP as reporter. This reporter has reduced half-
life compared to EGFP. Over 200 puror pTARG2 transfect-
ants were screened, but none completely silenced GFP
expression in the presence of tet. Flow cytometric profiles
of the best-regulated clones are shown in Fig. 2C. When a
target construct (pTARG3) with an improved TRE was
used, 8 of 63 puror clones analysed had uninduced GFP
expression levels of less than twice the background level,
but these showed heterogeneous GFP expression in the
absence of tet (Fig. 2D). Experiments with the methyla-
tion inhibitor 5-aza-2'deoxycytidine (AZC) indicated that
heterogeneous expression was caused by DNA methyla-
tion of the tTA gene [30]. For example, when T15, one of
the clones transfected with pTARG3, was treated with AZC
for 24 h, a marked increase in GFP-expressing cells was
observed (Fig. 2E). Furthermore, luciferase expression in
the same clone transiently transfected with a luciferase
reporter gene linked to the improved TRE (pTIGHT-luc,
Clontech) was also stimulated (2.6-fold) by a 24 h treat-
ment of the cells with AZC prior to the transfection (Meth-
ods). This latter experiment suggested that methylation of
the tTA gene, not the TRE, was responsible heterogeneous
expression. The relatively homogeneous GFP expression
seen in pTARG1 and pTARG2-transfected clones (Fig.
2C,D) probably reflects the use of lower passages of HT2
cells that were less likely to have suffered tTA gene silenc-
ing.
To minimise tTA gene methylation, the itTA-expressing
HT1080 line Rht14 was made (Methods) and used for a
final screening experiment. To allow subsequent testing of
both ScIn-1 and ScIn-2, an FRT-tagged target construct
(pTARG4) was used. Of 32 puror clones analysed, 7 had
uninduced GFP expression levels of <2-fold above back-
ground combined with acceptable single-peak profiles
(Fig. 2F), while others showed heterogeneous expression
(Fig. 2G). The two best clones (Rht14-10 and Rht14-19)
were chosen for further analysis.
Both Rht14-19 and Rht14-10 were found by Southern
blot analysis (not shown) to carry a single copy of
pTARG4. To test for stability of expression, clone Rht14-
10 was cultured continuously for 42 days during which
time the profile of GFP expression remained largely
unchanged (Fig. 2H). A comparison of flow cytometric
and immunoblot analyses of tet-induced GFP down-regu-
lation in clone Rht14-19 illustrates one of the advantages
of screening by flow cytometry, namely its sensitivity (Fig.
2I). Thus, substantial above-background GFP expression,
readily detectable by flow cytometry, is undetectable on
immunoblots. A second advantage of flow cytometric
screening is its ability to detect and eleminate heterogene-
ously expressing clones, such as those in Fig. 2D and 2G,
which would have been difficult or impossible to identify
by bulk measurements of GFP expression (e.g. by immu-
noblot).
ScIn-1 insertion
The insertion construct pIN-1 (Fig. 1B) was co-lipofected
with a Cre expression construct (pMC-Cre) into 5 × 105
Rht14-19 cells to generate 53 hygromycin-resistant
(hygror) colonies. In a control experiment, identical
except for the omission of pMC-Cre, no hygror colonies
were generated. Of 48 hygror colonies examined, 47 hadBMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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lost GFP expression and became sensitive to hygromycin
when tet was added (not shown), both expected conse-
quences of the desired integration event. DNA fragments
diagnostic for the expected insertion event were detected
in all (10/10) of the GFP-negative, hygror clones analysed
by PCR and Southern blots (Fig. 3A–C). The same 10
clones also showed similar patterns of tet-regulated luci-
ferase expression (Fig. 3D). These results show that the
desired Cre-mediated insertion step occurs at a frequency
of approximately10-4 per transfected cell (Table 1) to gen-
erate tet-regulated GOI expression in a reproducible man-
ner. Given the stringency of GFP expression in clone
Rht14-19, the background of luciferase expression in the
insertion clones was surprisingly high. Based on the better
stringencies obtained with clone Rht14-19 using ScIn-2
(next section), this background may indicate some activa-
tion of the TRP by unidentified sequences in pIN-1.
ScIn-2 insertion
The insertion construct pIN-2 (Fig. 1C) was co-lipofected
with pMC-Cre into 5 × 105 Rht14-10 or Rht14-19 cells to
generate 11 and 32 MPA/X-resistant (MPA/Xr) colonies,
respectively. No MPA/Xr colonies developed in the control
transfections lacking pMC-Cre. Of the 11 Rht14-10-
derived colonies, 9 had lost GFP expression and became
sensitive to MPA/X when tet was added (not shown). Of
the 32 Rht14-19-derived colonies, 22 had lost GFP expres-
sion and became sensitive to MPA/X when tet was added
(not shown). Nine GFP-negative, MPA/Xr clones from
each parental clone were analysed by genomic PCR, and
all were positive for the 629 bp PCR product diagnostic
for the expected integration (Fig. 4A,B). Four insertion
clones, one derived from Rht14-10 (10IN5) and three
from Rht14-19 (19IN3, 19IN4 and 19IN5), were analysed
by Southern blot and all showed the expected change in
structure (Fig. 4A,C). Together, these results indicate that
the desired insertion event occurred at frequencies of 1.8
× 10-5 and 4.4 × 10-5 per transfected cell in clones Rht14-
10 or Rht14-19, respectively (Table 1).
Flp-mediated deletion
Two insertion clones (10IN5 and 19IN5), one of each
parental type, were chosen for Flp-mediated deletion.
Cells grown with tet (without MPA/X) for at least 72 h
were lipofected (without [10IN5] or with [19IN5] tet for
4 h; see methods) with the Flp expression plasmid
pCAGGS-flpe (Cambion), and cultured at low density
with tet until colonies appeared. Colonies were analysed
by genomic PCR. For Flp-treated 10IN5 cells, 16 pools (6
clones/pool) were assayed and 9 pools produced the pre-
dicted 472 bp PCR product (Fig. 4Ac) indicative of Flp-
mediated deletion (Fig. 5A). Individual clones from two
positive pools (5 and 9) were analysed by the same PCR
assay and 6/12 were positive for the 472 bp product (Fig.
5A). The efficiency of flp-mediated deletion was thus at
Screening for well-regulated GFP expression Figure 2
Screening for well-regulated GFP expression. A. Sche-
matic (not to scale) of the target constructs used. DNA is 
represented as in Fig. 1. Pale and dark ellipses represent orig-
inal and improved TRP, respectively. B-I. Flow cytometric 
profiles (y-axis, counts; x-axis, GFP fluorescence [FLH1]) of 
clones isolated after transfection with plasmids shown in A. 
For profiles in B (left only), C, D, F and G the green and yel-
low traces represent cells grown with or without tet, respec-
tively, and the red traces represent GFP-negative cells (Rht14 
or HT1080). B. Left: Clone 6, the most stringently regulated 
clone isolated after transfection of pTARG1 into HT2 cells. 
Right: GFP expression profile of Clone 6 at indicated times 
after addition of tet. C. Four of the most stringently regu-
lated clones isolated after transfection of pTARG2 into HT2 
cells. D. Three of the most stringently regulated clones iso-
lated after transfection of pTARG3 into HT2 cells. E. Effect 
of AZC on GFP expression in T15, a pTARG3-transfected 
HT2 clone. Cells were cultured with (green) or without 
(blue) AZC for 24 h, and then for a further 24 h without 
AZC, before analysis. F. Four of the most stringently regu-
lated clones isolated after transfection of pTARG4 into 
Rht14 cells. G. GFP expression profile of two heterogene-
ously expressing clones isolated after transfection of Rht14 
with pTARG4. H. Profile of clone Rht14-10 grown continu-
ously with passaging for 14 d or 42 d. I. GFP expression in 
clone Rht14-19, as measured by immunoblot (top) or flow 
cytometry (bottom), at the indicated times after addition of 
tet.BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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least 0.14 (13/96), and probably closer to 0.28 (6/12 × 9/
16), events per transfected cell. A Southern blot of two
such clones (10flp9.2 and 10flp9.3) was consistent with
the predicted structures (Fig. 4A,C). The 7 Flp-deleted
clones showed highly stringent tet-regulated luciferase
expression (Fig. 5B). Above-background levels of unin-
duced luciferase expression were detectable, but all clones
showed induction ratios approaching 10,000-fold, con-
sistent with the GFP inducibility of parental clone Rht14-
10.
For Flp-treated 19IN5 cells, 12 pools (6 clones/pool) were
assayed by PCR (Fig. 5C). Two pools (9 and 12) were pos-
itive, each due to the presence of a single clone 19flp9.2
and 19flp12.3, respectively. The relatively low efficiency
of Flp-mediated deletion in 19IN5 (0.03 [2/72] events per
transfected cell) probably reflects a lower efficiency of
pCAGGS-flpe delivery due to the inclusion of tet in lipo-
fection mix of that particular transfection. Southern blot
(Fig. 4C) and PCR analysis (Fig. 5C), showed that
19flp9.2 was impure, the majority of cells being of paren-
tal (19IN5) type. Southern analysis of the other flp-
deleted clone (19flp12.3), however, confirmed that it had
undergone the expected deletion (Fig. 4C). Clone
19flp12.3 showed highly stringent tet-regulation of luci-
ferase expression with an induction ratio of more than
10,000-fold and uninduced expression levels barely
above background (Fig. 5D).
Use of ScIn-2 to generate cells with inducible I-SceI or 
Rad52 expression
Having validated the ScIn method, we put it into practice
using ScIn-2 with genes for I-SceI or Rad52 as our GOIs.
For these experiments a modified insertion pIN-2 vector
(pIN2-neoMCS) was used with a different selectable
marker gene (neo in place of gpt) followed by a multiple
cloning site (Fig. 6A). The open reading frames (ORFs)
encoding I-SceI or Rad52, the former with a N-terminal
Haemaglutinin (HA) tag, were cloned into pIN2-neoMCS
to generate pIN2-neoSCE and pIN2-neoR52. These plas-
Cre-mediated insertion by ScIn-1 Figure 3
Cre-mediated insertion by ScIn-1. A. Schematic (not to 
scale) of the target locus in clone Rht14-19 before (top) and 
after (bottom) Cre-mediated insertion of pIN-1. DNA is rep-
resented as in Fig. 1 with recognition sites for DraI (D) and 
PCR primers indicated. B. Ethidium bromide stained agarose 
gel of electrophoresed PCR products generated with the 
primers in A, and pTIGHTluc (Clontech) DNA (+), no DNA 
(-) or cell pellets of 10 hygr, GFP-negative clones (1–10) 
selected after transfection of Rht14-19 with pIN-1 and pMC-
Cre. M= marker DNA. C. Southern blots of genomic DNA 
isolated from Rht14-19 (+) and the same Rht14-19 deriva-
tives described in B digested with DraI. The probe was from 
the d2EGFP cassette. M = marker DNA. D. Luciferase activ-
ity in lysates from Rht14-19 (Rh) or the same Rht14-19 
derivatives (1–10) described in C, grown in the absence or 
the presence (for 48 h.) of tet.
Table 1: Frequencies of Cre-mediated insertion events
a Host cell Insertion 
construct
b Cre Drug 
Selection
c Colonies d GFP-neg e Tet f PCR/SB g I
Rht14-19 pIN-1 + hyg 53 47/48 47/48 10/10 10
Rht14-19 pIN-1 - hyg 0 - - - 0
Rht14-10 pIN-2 + MPA/X 11 9/11 9/11 9/9 1.8
Rht14-10 pIN-2 - MPA/X 0 - - - 0
Rht14-19 pIN-2 + MPA/X 32 22/33 22/33 9/9 4.4
Rht14-19 pIN-2 - MPA/X 0 - - - 0
Rht14-10 pIN2-
neoMCS
+ G418 188 181/188 NT NT 36
Rht14-10 pIN2-neoSCE + G418 169 163/169 3/3 3/3 33
Rht14-10 pIN2-neoR52 + G418 226 217/226 3/3 3/3 43
a Each row represents data for the transfection of 5 × 105 cells.
b Indicates whether pMC-Cre was (+) or was not (-) co-transfected.
c Total number of drug-resistant colonies generated.
d Colonies that did not express GFP.
e GFP-negative colonies that became drug-sensitive on addition of tet.
f GFP-neg/Tets colonies with expected structure detected by PCR or Southern Blot.
g Cre-mediated insertion frequency expressed as events per transfected cell × 105 (assuming all GFP-neg clones are correctly inserted).BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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mids were co-lipofected with pMC-Cre into Rht14-10 and
G418r colonies were selected, > 96% of which had lost
GFP expression. Of six such clones tested, three each of
the pIN-neoSCE- and pIN-neoR52-transfected clones, all
were found to become sensitive to G418 in tet and to be
positive in PCR assays for targeted integration (Fig. 6B,C).
In this way site-specific insertion frequencies of between
3.3 and 4.3 × 10-4 were estimated for pIN2-neoMCS and it
derivatives, at least 20-fold higher than with pIN-2.
Two clones, 10IN-SCE.1, 10IN-R52.1 (with pIN2-neoSCE
and pIN2-neoRAD52 integrated, respectively) were grown
in +tet medium, lipofected (- tet for 4 h; see methods)
with pCAGGS-flpe and plated at low dilution in +tet
medium. The majority of the resulting colonies were pos-
itive in a PCR assay for the deletion event, suggesting
highly efficient Flp-mediate deletion (Fig. 6C–E). Two
clones of high purity (10IN-SCE.1flp1, 10IN-R52.1flp1)
as judged by PCR were analysed further. Immunoblot
analyses confirmed the expected tet-regulated expression
of the appropriate GOI (I-SceI or Rad52) in these clones
(Fig. 6F). Expression in the presence of tet was undetecta-
ble indicating, as far as is possible by immunoblotting,
highly stringent tet-regulation.
To test for functionality of the induced I-SceI, and as a
more robust test for the stringency of tet-regulation, 10IN-
SCE.1flp1 was transfected with pDRneo [31]. This sub-
strate for homologous recombination carries a functional
hygromycin resistance cassette flanked by two defective
neo cassettes, one being disrupted in its coding sequence
by the 18 bp recognition site for I-SceI. Cleavage of the
first neo cassette by I-SceI greatly stimulates its conversion
to a functional neo cassette by homology directed DNA
repair using the second neo cassette as a template. Before
transfection with pDRneo, the purity of 10IN-SCE.1flp1
was further demonstrated by plating three million cells in
G418 without tet: no colonies formed even though paren-
tal 10IN-SCE.1 cells grow in these conditions. Following
transfection of 10IN-SCE.1flp1 with pDRneo, three
Hygror  clones, selected and expanded with tet in the
growth medium, were tested for the presence of G418r
cells after a period (2 days) of growth with or without tet.
The results (Table 2) show that I-SceI induction causes >
104-fold stimulations in gene conversion, with absolute
frequencies reaching 3–7% of all cells. These effects are at
least as pronounced as those previously described after
transient transfection of an I-SceI expression construct
[31]. Variations between clones in the absolute frequen-
cies of G418r are most likely caused by different chromo-
somal position effects on the integrated pDRneo. The low
frequencies of G418r colonies (1–5 × 10-6) detected in the
continuous presence of tet are likely to reflect spontane-
ous recombination of the pDRneo substrate rather than
recombination stimulated by residual I-SceI expression:
similar frequencies of spontaneous G418r  have been
described for pDRneo in HT1080 [32], HEK293 [32] and
CHO [31] cells that have never been transfected with an I-
SceI gene. Furthermore, these frequencies are no higher
than the spontaneous G418r  frequency (1.3 × 10-5)
observed for a hygror clone derived from pDRneo-trans-
fected Rht14 cells (Table 2). This frequency was also unaf-
fected by tet removal, excluding the possibility that tet
reduced G418r  colony formation independently of its
effect on I-SceI expression. Taken together, these results
clearly demonstrate that I-SceI is functional and regulated
with very high stringency following its targeted integra-
tion by use of the ScIn-2 method.
Discussion
The "Screen and Insert" (ScIn) methods described here
provide convenient and reproducible ways to isolate
clones in which transgene expression is stringently regu-
lated by tet. A great variety of modifications and improve-
ments to the original Tet-Off system have been reported.
Versatility, convenience, stringency and stability have
been variously extended by the development of the
reverse tTA (Tet-On) system [33], the combined use of tet-
regulated activation and repression [34,35], systems for
single-vector delivery and/or autoregulation [36-44] and
by modifications to the TRE [45-48] or the transactivator
protein/gene [18,28,49-52]. Despite such improvements,
the tet system remains subject to the influence of chromo-
some position effects, complicating the isolation of opti-
mally regulated clones. The ScIn methods address this
problem.
The key to ScIn is the combination of a powerful GFP-
based screen to identify optimal chromosomal loci, and
the use of SSR to target the insertion of transgenes at such
sites. Screening by flow cytometry is valuable because it
allows lines with even very small amounts of leaky expres-
sion, or with cellular heterogeneity of expression, to be
eliminated. Furthermore, for a given cell line, one can
envisage collecting a range of clones with different induc-
tion characteristics, from which one can choose the clone
most suitable for a particular application. The ease with
which many clones can be screened increases the chances
of finding one in which optimal regulation is achieved.
Although we screened clones individually here, it may be
even more convenient in future to use flow sorting to
purify and clone the best cells from a population of trans-
fectants.
It is important to note that, once screening has been used
to identify a clone (e.g. Rht14-10) with a stringently regu-
lated reporter, the use of SSR to insert the GOI at the
reporter locus is relatively labour-unintensive and can be
used repeatedly for different GOIs. In ScIn2, for example,
the following three steps are now sufficient to generate anBMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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HT1080 clone with any GOI under highly stringent tet-
regulation: i) Clone GOI into multiple cloning site of
pIN2-neoMCS and co-transfect with pMC-Cre into Rht14-
10, selecting for G418r colonies. ii) Expand a G418r/GFP-
colony, confirm G418r is tet-sensitive (optional), transfect
with pCAAGflpe (or similar) and plate at low density in
tet. iii) Identify one of the >10% of colonies that is no
longer G418r when tet is removed.
ScIn has at least three advantages over the standard
approach of immunoblot-screening of multiple clones
with randomly integrated GOI. First, no screening for GOI
expression is required to identify the desired clone. Sec-
ond, tet-regulation of the GOI is likely to be much more
stringent and lacking in cellular heterogeneity. Third, the
same protocol can be used repeatedly with different GOIs
to generate clones whose phenotypes can be compared
without the complication of differential expression levels.
These advantages will be attractive for a range of studies,
including in both gain- and loss-of-function experiments.
The expression of I-SceI provides a good illustration of the
former. Leaky expression of this endonuclease will lead to
repeated cutting and repair of any I-SceI recognition sites
Flp-mediated deletion and resulting luciferase expression in  Rht14-10IN5 and Rht14-19IN5 Figure 5
Flp-mediated deletion and resulting luciferase 
expression in Rht14-10IN5 and Rht14-19IN5. A. Ethid-
ium bromide stained agarose gel of electrophoresed PCR 
products generated with the primers O2 and O4 (Fig. 4A) 
and cell pellets of Rht14-10, Rht14-10IN5, pTIGHTluc (+) 
and Rht10IN5flp pools (top, 1–16) or clones constituting 
Rht10IN5flp pools 5 and 9 (bottom). Positive controls (+) 
used pTIGHTluc DNA (expected product: 517 bp). B. Luci-
ferase activity in lysates from clones indicated (*) in A, or 
control cells (Rh14-10), grown in the absence or the pres-
ence (for 48 h) of tet. C. Ethidium bromide stained agarose 
gel of electrophoresed PCR products generated with the 
primers O2 and O4 (Fig. 4A) and cell pellets of Rht14-19, 
Rht14-19IN5, and Rht19IN5flp pools (top, 1–12) or constitu-
ent clones of pools 9 and 12 (bottom, 1–6). Positive controls 
(+) were as in A. D. Luciferase activity in lysates from clones 
indicated (*) in C, or control cells (Rht14-19), grown in the 
absence or the presence (for 48 h) of tet. Results of two 
experiments are shown.
Cre-mediated insertion by ScIn-2 Figure 4
Cre-mediated insertion by ScIn-2. A. Schematic (not to 
scale) of the target locus in clone Rht14-19 or Rht14-10 
before (a) and after (b) Cre-mediated insertion of pIN-2, and 
after flp-mediate deletion (c). DNA is represented as in Fig. 1 
with recognition sites for HindIII (H) and BglII (B) and PCR 
primers indicated. B. Ethidium bromide stained agarose gel 
of electrophoresed PCR products generated with the prim-
ers O1 and O3 and cell pellets of 9 MPA/Xr, GFP-negative 
clones selected after transfection of Rht14-10 (Rht14-10IN) 
or of Rht14-19 (Rht14-19IN) with pIN-2 and pMC-Cre. M = 
marker DNA. Negative (-) and positive (+) controls used, 
respectively, no DNA and pTIGHTgpt DNA (expected prod-
uct: 555 bp). C. Southern blots of genomic DNA isolated 
from Rht14-10 and derivatives and digested with BglII (left), 
or from Rht14-19 and derivatives and digested with HindIII 
(right). Derivatives before (10IN5 and 19IN3, 4 and 5) and 
after (10flp9.2 and 3 and 19flp9.2 and 12.3) Flp-mediated 
deletion are analysed. The probe was a fragment of the 
d2EGFP gene (methods).BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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in the host genome, until inaccurate repair by non-
homologous end-joining [53] results in the loss of I-SceI
sites. The ability to induce DSB, and measure cellular
responses, will therefore be irreversibly lost if expression
is leaky. The importance of minimal leakiness in loss-of-
function experiments is illustrated by systems in which a
tet-regulated transgene is expressed in cells whose corre-
sponding endogenous alleles have been inactivated
[13,14]. Switching off the tet-regulated transgene in such
systems will produce a true null phenotype only when
there is no leakiness.
Success of the ScIn method depends on optimal reporter
gene regulation from the target construct and this was
achieved best with pTARG4. Stringent regulation from the
other contructs (pTARG1-3) was limited by use of the
original TRE and/or by host cells that expressed tTA rather
itTA. Although we saw no signs of structural instability or
unstable gene expression at pTARG4 loci, the persistence
of prokaryotic vector sequences at transgene loci can in
some circumstances be problematic [54-56]. Removal of
unwanted vector DNA from target and insertion con-
structs prior to transfection might therefore be considered
desirable. For target constructs this may be achieved sim-
ply by digestion with appropriate restriction enzymes. For
insertion constructs, which must remain circular, this
might be achievable by inclusion of a second loxP site and
use of Cre recombinase in vitro.
The use of SSR to integrate transgenes at sites that support
tissue-specific or ubiquitous expression in mice is estab-
lished [57,58]. For tet-regulated expression, SSR has been
used to target either to defined loci, such as the HPRT [59]
or ColA1 [19] genes in mouse embryonic stem (ES) cells,
and the DHFR locus in Chinese Hamster Ovary (CHO)
cells locus[22], or to specific but undefined loci in e.g.
CHO [22], human cervical [22] and rat pancreatic cells
[20]. While these systems introduce the valuable aspect of
reproducibility into transgene integration in a given cell
line, the chosen target sites are not necessarily optimal for
stringency or for cellular homogeneity of induction. Fur-
thermore, establishing these systems in new cell lines is
demanding.
In an approach more closely related to ScIn, Puttini et al
[60] used I-SceI-stimulated homologous recombination
(HR) to target transgenes to a locus that was identified by
its ability to support stringent tet-regulation of another
reporter, secreted alkaline phosphatase (SEAP). In prac-
tice, this approach was limited by the low efficiency of
HR-mediated integration, the inability to use SEAP assays
to assess cellular heterogeneity and the presence of a pro-
moter/enhancer close to the TRE. In another approach
related to ScIn, a tet-regulated gpt gene was linked to a pro-
moterless GOI and randomly integrated into the genome
Use of ScIn-2 method for stringent tet-regulated expression  of I-SceI and Rad52 Figure 6
Use of ScIn-2 method for stringent tet-regulated 
expression of I-SceI and Rad52. A. Schematic (not to 
scale) of pIN2-neoMCS. DNA is represented as in Fig 1. 
MCS, multiple cloning site. B. Schematic (not to scale) of tar-
get locus on Rht14-10 after Cre-mediated insertion of pIN2-
neoSCE or pIN2-neoR52. C. Ethidium bromide stained agar-
ose gel of electrophoresed PCR products generated with the 
primers O2 and O5 on cell pellets of three pIN2-neoSCE- 
and three pIN2-neoR52-transfected Rht14-10 derivatives. 
Negative (-) and positive (+) controls were, respectively, no 
cells and cells (TetNeo, see methods) with an integrated tet-
regulated neo cassette (expected product: 944 bp). Clones 
chosen for flp-mediated deletion (10IN-SCE.1 and 10IN-
R52.1) are arrowed. D. As in B but after Flp mediated dele-
tion. E. Ethidium bromide stained agarose gel of electro-
phoresed PCR products generated with the primers O2 and 
O6 on clones derived from 10IN-SCE.1 (1–12, left) and prim-
ers O2 and O7 on clones derived from 10IN-R52.1 (1–12, 
right). Control reaction contained no cells (-) or genomic 
DNA generated from pools of flp-treated pIN2-neoSCE/
pIN2-neoR52 cells (+). Clones chosen for further analysis 
(10IN-SCE.1flp1 and 10IN-R52.1flp1) are arrowed. F. Immu-
noblot analysis of I-SceI and Rad52 expression in Rht14-10 
and, respectively in 10IN-SCE.1flp1 or 10IN-R52.1flp1 at the 
indicated times after removal or tetracycline.BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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[27]. After selecting clones with optimally-regulated gpt,
SSR was use to invert the DNA segment carrying gpt and
GOI, placing the GOI under control of a TRE. This system
suffered from the low stringency of gpt selection and the
need to select optimally-regulated clones for each new
GOI.
Emphasis in this paper has been on the use of transgenes
for the analysis of gene function in cultured cells. The ScIn
may also be valuable when extended to mice. For this,
however, methods must be developed to screen for ES cell
clones that support tet-regulated GFP expression not just
in culture, but also in all tissues of ES-derived animals.
Provided its tTA/rtTA gene can be deleted (e.g. by SSR),
the chosen clone can then be used repeatedly for the tar-
geted insertion of any GOI, and the generation of mice to
be crossed with transgenic lines chosen for their tissue-
specific expression of tTA/rtTA.
Conclusion
The screen and insert approach described is a highly effec-
tive way to achieve stringent and reproducible tet-regu-
lated transgene expression. Reagents developed here (e.g.
clone Rht14-10 and the insertion vector pIN2-neoMCS)
can be used immediately in a simple 3-step protocol to
achieve such expression in an HT1080 background. Fur-
thermore, additional reagents we describe (e.g. pTARG4),
can be used to establish the select and insert method in
other cell lines. The method is particularly attractive for
analyses of gene function in situations where the gene
product is likely to have biological effects even when
expressed at very low levels and/or where the effects of
several related genes are to be compared. Cell lines
expressing stringently regulated I-SceI or Rad52, generated
in the course of this study, will be useful in studies of DNA
damage and repair.
Methods
Target plasmids
pTARG1
A lox71 site (annealed oligonucleotides 5'-TACCGTTCG-
TATAGCATACATTATACGAAGTTAT-3' and 5'-
CTAGATAACTTCGTATAATGTATCGTATACGAACGG-
TAGC-3') was ligated to the SacII and XbaI sites of
pUHD10-3 ([29], kindly donated by H. Bujard, ZMBH,
Heidelberg) to create pTRElox71. To generate pTARG1, an
XbaI fragment from pEGFP (Clontech), carrying the EGFP
open reading frame (ORF), was inserted at XbaI site down-
stream of the lox71 site of pTRElox71.
pTARG2
The ORF of d2EGFP (from pd2EGFP, Clontech) was iso-
lated as a NotI/AgeI fragment and inserted into the NotI/
AgeI sites of pTRElox71.
pTARG3
A lox71 site (annealed oligonucleotides 5'-
AATTCTACCGTTCGTATAGCATACATTATACGAAGT-
TATACTAGTG-3' and 5'-
GATCCATCAGTATAACTTCGTATAATGTATGCTATACGAA
CGGTAG3') was cloned into the EcoRI and BamHI sites of
pTRE-TIGHT (Clontech), creating pTlox71. To generate
pTARG3, the ORF of d2EGFP (from pd2EGFP, Clontech)
was isolated as a NotI/BamHI fragment and inserted into
the NotI and BamHI sites of pTlox71.
pTARG4
An FRT site (annealed oligonucleotides 5'-
AATTAGATCTGAAGTTCCTATTCTCTAGAAAGTATAG-
GAACTTC-3' and 5'-AATTGAAGTTCCTATACTTTCTAGA-
GAATAGGAACTTCAGATCT-3') was cloned into the
HindIII/NcoI sites of pTARG3.
Insertion plasmids
pIN-1
A  lox66  site (annealed oligonucleotides 5'-
TCGAGAATTCATAACTTCGTATAGCATACATTATAC-
GAACGGTAG-3' and 5'-AGCTCTACCGTTCGTATAATG-
TATCGTATACGAAGTTATGAATTC-3') was cloned into the
XhoI/HindIII sites of pGL3-Basic (Clontech) to generate
plox66luc. To generate pIN-1, pIRESHyg3 (Clontech) was
digested with XhoI/NheI and the IRES-Hyg fragment was
cloned into the XbaI/SalI site of plox66luc, downstream of
the luciferase ORF.
Table 2: Frequencies of G418r colony formation in pDRneo-transfected cells
Cells Frequency of G418r Fold Induction
+ tet - tet
a 10IN-SCE.1flp1/DRneo, Clone 1 4.7 × 10-6 7.2 × 10-2 1.5 × 104
a 10IN-SCE.1flp1/DRneo, Clone 2 1.3 × 10-6 2.9 × 10-2 2.2 × 104
a 10IN-SCE.1flp1/DRneo, Clone 3 1.0 × 10-6 3.5 × 10-2 3.5 × 104
b Rht14/DRneo 1.3 × 10-5 1.4 × 10-5 1.1
a Three independent pDRneo-transfected 10IN-SCE.1flp1 clones were grown continuously with tet in the medium (+tet) or tet was withdrawn for 
48 h. (-tet) prior to G418 selection (methods).
b A single hygror clone, isolated after the transfection of Rht14 cells with pDRneo, was grown for 48 h. and then selected in G418, with tet either 
present (+tet) or not present (-tet) in the medium throughout (methods).BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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pIN-2
The gpt ORF was removed from pBSgpt [61] as a BamHI/
BglII fragment and cloned into the BglII site of pGL3-Basic
(Clontech) to make pGL3gptluc. A lox66 site (annealed oli-
gonucleotides 5'-CTAGATAACTTCGTATAGCATACAT-
TATACGAACGGTAGAAT-3' and 5'-
TCGAATTCTACCGTTCGTATAATGTATGCTATACGAAGT-
TAT-3') was then cloned into the NheI/XhoI sites of
pGL3gptluc upstream of the luciferase ORF to make
plox66gptluc. To generate pIN-2, an FRT site (annealed oli-
gonucleotides 5'-AGCTGAAGTTCCTATTCTCTAGAAAG-
TATAGGAACTTCGAATT-3' and 5'-
CATGAATTCGAAGTTCCTATACTTTCTAGAGAATAG-
GAACTTC-3') was cloned into the HindIII/NcoI sites of
plox66gptluc located between the luciferase and gpt ORFs.
pINneoMCS
An MCS (annealed oligonucleotides 5'-
CGCTAGCAGCTGGTCCGCGGACTAGTCCCGGGAAGCT
TCTCGAGAGGCCTCATATGCATGCCATGGCCGG-3' and
5'-CCATGGCATGCATATGAGGCCTCTCGAGAAGCTTC-
CCGGGACTAGTCCGCGGACCAGCTGCTAG-3') was
inserted into BstBI/FseI sites of pIN-2, removing the luci-
ferase ORF, to create pIN2-MCS. pSV2neo (Southern et al.,
1982) and plox66gptLuc were cut with BglII and BamHI
and neomycin ORF was cloned downstream of the lox66
site to create plox66Neo. To create pIN2-neoMCS, pIN2-
MCS and plox66neo were cut with BglII and PfmI and the
gpt ORF was replaced with the neomycin ORF.
pIN2-neoSCE and pIN2-neoR52
pIN2-neoMCS was cut with EcoRI, end-filled then cut with
SalI. pFB580 (human RAD52 cDNA cloned into pUC18, a
kind gift from F. Benson and S. West, Cancer Research UK,
London) and pCMV3xnls-I-SceI ([62], a kind gift from M.
Jasin, Sloane Kettering Institute, New York) were also cut
with  EcoRI, end-filled then cut with SalI, to release the
RAD52  and I-SceI ORFs, respectively. RAD52  and  I-SceI
ORFs were then cloned into pIN2-neoMCS to generate
pIN2-neoR52 and pIN2-neoSCE, respectively.
plox66Neo
plox66Neo (see above) and pSV2neo were digested with
BglII and BamH1 and the neo ORF was cloned downstream
of the lox66 site.
Other plasmids
A plasmid (pRK5-itTA) encoding the improved transacti-
vator itTA [28] was kindly donated by R. Sprengel, Max-
Planck-Institute, Heidelberg. The itTA ORF was cloned as
an EcoR1/BclI fragment into the EcoRI/BclI sites of pZeoSV
(Invitrogen), to create pZeoSVitTA. pTIGHTgpt was made
by inserting the gpt ORF as a BglII/BamH1 fragment from
pBSgpt into the BamH1 site of pTRE-TIGHT.
Cell culture
Conditions used for the culture of HT1080 cells and deriv-
atives have been described previously [63]. When
required the medium was supplemented with one or
more of the following drugs: 5-azacytidine (1 μM), hygro-
mycin B (100 μg/ml), mycophenolic acid (10 μg/ml),
puromycin (0.4 μg/ml), tetracycline (1 μg/ml), xanthine
(100  μg/ml) and zeocin (200 μg/ml). HT-2 cells have
been described [27] and were also called HTET [13]. A tel-
omerase-immortalised human retinal epithelial cell line
(hTERT-RPE1; Clontech) was cultured in a similar manner
to HT1080 cells.
Cell lines generated by electroporation
Electroporation with a Gene Pulser (BioRad) was as
described [64]. Rht14 cells were made by electroporation
of HPRT+ HT1080 cells with 10 μg BglII-linearised pZeoS-
VitTA. Zeocinr colonies were screened by lipofection (see
below) with pTIGHTLuc (Clontech) grown in the pres-
ence or absence of tetracycline. After 48 hours, lysates
were prepared and assayed for luciferase. Rht14 was cho-
sen from among 24 colonies for its low luciferase activity
in the presence of tet and its high induction ratio. Co-elec-
troporation was used to generate clones with randomly
integrated target plasmids. Target plasmid (20 μg) was lin-
earised with PvuI (pTARG1) or BglI and SspI (pTARG2,
pTARG3, pTARG4), gel-extracted, ethanol-precipitated
and co-electroporated with 1 μg of similarly purified, SpeI-
linearised pBL-PuroR [32], into Rht14 cells. Puror colonies
identified as GFP-positive by fluorescence microscopy
(Zeiss Axiovert S100TV microscope) were picked for fur-
ther analysis.
Lipofection
Lipofectamine 2000 (Invitrogen) was used for delivery of
insertion constructs and transient expression of Cre and
Flp recombinases and luciferase. 24 hours prior to trans-
fection, 250,000 cells were plated into 6-well plates in 2
ml of antibiotic-free (- tet, unless otherwise stated)
medium. On the day of transfection a DNA/Lipo-
fectamine/OptiMEM mix was prepared (0.5 ml/well)
according to the manufacturer's instructions and incu-
bated with the cells for 4 hours, after which the mix was
replaced with fresh medium. For Cre-mediated insertion,
2 μg of insertion construct and 2 μg of pMC-Cre15 (kindly
donated by H. Gu, University of Köln) were used per well.
The following day, the cells were seeded into 9 cm plates
(105 cells per plate) and the appropriate drug selection
was added after a further 24 hours. For flp-mediated exci-
sion, 4 μg of pCAGGS-flpe (Cambion) was used per well
and cells were plated the following day at low density
(50–500 cells per 9 cm [diam] dish) in medium with tet.
To analyse the effect of AZC on luciferase expression from
pTIGHT-luc, clone T15 cells were grown with or without
AZC for 24 h, then plated in antibiotic-free medium andBMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
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lipofected 24 h later (as above) with pTIGHT-luc (4 μg).
After a further 24 h lysates were prepared and assayed for
luciferase (see below).
Flow cytometry
Cells were grown in 6-well plates with or without tet for
48–72 hours (except where longer times are indicated)
prior to FACS analysis. Cells, generally no more than 80%
confluent on the day of analysis, were trypsinised and
resuspended in cold phosphate buffered saline (PBS) at a
density of 1000 cells per μl. 40,000 cells were analysed in
a FACScan machine (Becton Dickinson) with an argon
laser tuned to 488 nm (FL-1; with fluorescence channel
FL-3 as a control). Acquisition, storage, and analysis of
data were carried out using CellQuest software (Becton
Dickinson).
Immunoblots
Immunoblots were carried out as described previously for
Rad52 [65]. For GFP detection, a primary monoclonal
antibody was used (Clontech, 632380; 1/1000 dilution)
and a secondary, horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin antibody (Sigma, P-0447;
1/1000 dilution) was used. For HA-tagged I-SceI detec-
tion, the primary antibody was a rat monoclonal (Roche,
3F10; 1/500 dilution) and the secondary a horseradish
peroxidase-conjugated goat anti-rat immunoglobulin
antibody (Sigma, A-9037; 1/1000 dilution)
Polymerase Chain Reactions (PCR)
Cell pellets (100–10,000 cells) were resuspended in a 25
μl Taq polymerase buffer (Qiagen) containing pronase
(0.6 μg/μl), incubated at 50°C for one hour, 95°C for 10
minutes and then placed on ice. A mix (25 μl) containing
nucleotides (Pharmacia, 0.5 μM), Taq polymerase (Qia-
gen, 1.25 U) and oligonucleotides (100 ng each) dis-
solved in in Taq polymerase buffer was added. Annealing
temperatures (Ta) for the various primer pairs were 60°C
(O2/O4 and O1/O3), 63°C (O2/O5), and 57°C (O2/O6
and O2/O7). Temperature sequences were: 95°C (10
min.) then 30 cycles of 95°C, Ta, and 72°C (1 min each)
then 72°C (10 min.). Primers were: O1 (5'-ACGAG-
GCCCTTTCGTCTTCA-3'), O2 (5'-TTTAGTGAACCGTCA-
GATCGCC-3'), O3 (5'-CCACGGCTTACGGCAATAATGC-
3'), O4 (5'-CCCCTTTTTGGAAACGAACAC-3'), O5, (5'-
AGAAGGCGATAGAAGGCGATGC-3'), O6 (5'-ACTC-
GAACTGCATACAGTAG-3') and O7 (5'-CCAAAGA-
TAAAGCCTTGGAC-3').
As positive controls for the DNA template, ~10 pg of the
indicated plasmid DNA, or genomic DNA from 1000 pel-
leted cells of the indicated cell line, were used. TetNeo
cells have a tet-regulated neo gene and are described in
detail elsewhere [30]. Briefly, plox66Neo was inserted by
Cre-mediated recombination into tTERT-RPE1 cells with
an integrated pTARG4 supporting tightly regulated GFP.
PCR products were analysed by standard agarose gel elec-
trophoresis with 1 kb ladder marker DNA (Invitrogen).
Southern blots
Standard methods were used, as previously described
[61]. The GFP probe was a 727 bp NcoI fragment from
pd2EGFP [Clontech]). Marker DNA was end-labelled 1 kb
ladder (Invitrogen).
Luciferase assays
A commercial kit (Promega) was used according to man-
ufacturers instructions. Briefly, cells were seeded at 105
cells per 3.5 cm (diam.) well, incubated in medium with
or without tet for 48 hours, then washed with PBS and agi-
tated gently for at least 20 minutes with 500 μl passive
lysis buffer. The cell lysate was cleared by centrifugation
and 20 μl added to 100 μl of luciferase assay reagent in a
luminometer tube. The relative light units (RLU) were
measured immediately in a Biorbit 1253 luminometer.
The average of ten RLU measurements taken at 2-second
intervals was recorded.
Recombination of pDRneo
To estimate the recombination frequency when I-SceI was
not expressed, 3 million cells were distributed in three 15
cm (diam.) plates and selected in G418 and tetracycline
and colonies counted after 14 d. To determine the fre-
quency after I-SceI induction, cells were grown in the
absence of tet for 48 h and then plated (at 50, 100, 250
cells per 9 cm [diam.] plate) in G418 and tetracycline and
colonies counted after 14 d. To account for the plating
efficiency, the proportion of G418r clones was calculated
as a fraction of the total number of colonies formed when
compared to the amount generated on equivalent unse-
lected (no G418) plates. Rht14/DRneo cells were analysed
in the same way except that tet was either present or
absent from the growth medium throughout, and for 48
h prior to, G418 selection.
Authors' contributions
RB carried out most of the experimental design and imple-
mentation, and prepared the draft manuscript. AMP car-
ried out some preliminary studies including the
generation of clone 6 (Fig. 2). ACGP conceived the basic
approaches taken, carried out some experimental work,
supervised the project, and prepared the final manuscript.
All authors read and approved the final manuscript.
Acknowledgements
We are grateful to Fiona Benson, Herman Bujard, Maria Jasin, Rolf Sprengel 
and Steve West, for generously supplying reagents. This work was funded 
by the MRC.BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
Page 13 of 14
(page number not for citation purposes)
References
1. Lewandoski M: Conditional control of gene expression in the
mouse.  Nat Rev Genet 2001, 2(10):743-755.
2. Mikkola HK, Orkin SH: Gene targeting and transgenic strate-
gies for the analysis of hematopoietic development in the
mouse.  Methods Mol Med 2005, 105:3-22.
3. Porter A: Controlling your losses: conditional gene silencing
in mammals.  Trends Genet 1998, 14(2):73-79.
4. Rajewsky K, Gu H, Kuhn R, Betz UA, Muller W, Roes J, Schwenk F:
Conditional gene targeting.  J Clin Invest 1996, 98(3):600-603.
5. Gossen M, Bujard H: Tight control of gene expression in mam-
malian cells by tetracycline-responsive promoters.  Proc Natl
Acad Sci U S A 1992, 89(12):5547-5551.
6. Blau HM, Rossi FM: Tet B or not tet B: advances in tetracycline-
inducible gene expression.  Proc Natl Acad Sci U S A 1999,
96(3):797-799.
7. Corbel SY, Rossi FM: Latest developments and in vivo use of
the Tet system: ex vivo and in vivo delivery of tetracycline-
regulated genes.  Curr Opin Biotechnol 2002, 13(5):448-452.
8. Shockett PE, Schatz DG: Diverse strategies for tetracycline-reg-
ulated inducible gene expression.  Proc Natl Acad Sci U S A 1996,
93(11):5173-5176.
9. Branda CS, Dymecki SM: Talking about a revolution: The
impact of site-specific recombinases on genetic analyses in
mice.  Dev Cell 2004, 6(1):7-28.
10. Sorrell DA, Kolb AF: Targeted modification of mammalian
genomes.  Biotechnol Adv 2005, 23(7-8):431-469.
11. Chang HS, Lin CH, Chen YC, Yu WC: Using siRNA technique to
generate transgenic animals with spatiotemporal and condi-
tional gene knockdown.  Am J Pathol 2004, 165(5):1535-1541.
12. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ,
Lowe SW: Probing tumor phenotypes using stable and regu-
lated synthetic microRNA precursors.  Nat Genet 2005,
37(11):1289-1295.
13. Carpenter AJ, Porter AC: Construction, characterization, and
complementation of a conditional-lethal DNA topoisomer-
ase IIalpha mutant human cell line.  Mol Biol Cell 2004,
15(12):5700-5711.
14. Sonoda E, Sasaki MS, Buerstedde JM, Bezzubova O, Shinohara A,
Ogawa H, Takata M, Yamaguchi-Iwai Y, Takeda S: Rad51-deficient
vertebrate cells accumulate chromosomal breaks prior to
cell death.  Embo J 1998, 17(2):598-608.
15. Martin DI, Whitelaw E: The vagaries of variegating transgenes.
Bioessays 1996, 18(11):919-923.
16. Olson EN, Arnold HH, Rigby PW, Wold BJ: Know your neighbors:
three phenotypes in null mutants of the myogenic bHLH
gene MRF4.  Cell 1996, 85(1):1-4.
17. Burgess-Beusse B, Farrell C, Gaszner M, Litt M, Mutskov V, Recillas-
Targa F, Simpson M, West A, Felsenfeld G: The insulation of genes
from external enhancers and silencing chromatin.  Proc Natl
Acad Sci U S A 2002, 99 Suppl 4:16433-16437.
18. Anastassiadis K, Kim J, Daigle N, Sprengel R, Scholer HR, Stewart AF:
A predictable ligand regulated expression strategy for stably
integrated transgenes in mammalian cells in culture.  Gene
2002, 298(2):159-172.
19. Beard C, Hochedlinger K, Plath K, Wutz A, Jaenisch R: Efficient
method to generate single-copy transgenic mice by site-spe-
cific integration in embryonic stem cells.  Genesis 2006,
44(1):23-28.
20. Thomas H, Senkel S, Erdmann S, Arndt T, Turan G, Klein-Hitpass L,
Ryffel GU: Pattern of genes influenced by conditional expres-
sion of the transcription factors HNF6, HNF4alpha and
HNF1beta in a pancreatic beta-cell line.  Nucleic Acids Res 2004,
32(19):e150.
21. Wang J, Sarov M, Rientjes J, Fu J, Hollak H, Kranz H, Xie W, Stewart
AF, Zhang Y: An improved recombineering approach by add-
ing RecA to lambda Red recombination.  Mol Biotechnol 2006,
32(1):43-53.
22. Wong ET, Kolman JL, Li YC, Mesner LD, Hillen W, Berens C, Wahl
GM:  Reproducible doxycycline-inducible transgene expres-
sion at specific loci generated by Cre-recombinase mediated
cassette exchange.  Nucleic Acids Res 2005, 33(17):e147.
23. Jasin M: Genetic manipulation of genomes with rare-cutting
endonucleases.  Trends Genet 1996, 12(6):224-228.
24. Johnson RD, Jasin M: Double-strand-break-induced homolo-
gous recombination in mammalian cells.  Biochem Soc Trans
2001, 29(Pt 2):196-201.
25. West SC: Molecular views of recombination proteins and
their control.  Nat Rev Mol Cell Biol 2003, 4(6):435-445.
26. Araki K, Araki M, Yamamura K: Targeted integration of DNA
using mutant lox sites in embryonic stem cells.  Nucleic Acids
Res 1997, 25(4):868-872.
27. Sullivan MJ, Carpenter AJ, Porter AC: A 'select and swap' strategy
for the isolation of clones with tightly regulated transgenes.
Eur J Biochem 2001, 268(6):1605-1612.
28. Krestel HE, Shimshek DR, Jensen V, Nevian T, Kim J, Geng Y, Bast T,
Depaulis A, Schonig K, Schwenk F, Bujard H, Hvalby O, Sprengel R,
Seeburg PH: A genetic switch for epilepsy in adult mice.  J Neu-
rosci 2004, 24(46):10568-10578.
29. Gossen M, Bujard H: Efficacy of tetracycline-controlled gene
expression is influenced by cell type: commentary.  Biotech-
niques 1995, 19(2):213-6; discussion 216-7.
30. Brough R: A novel approach for regulated transgene expres-
sion in mammalian cells.  In Clinical Sciences Volume PhD. London ,
Imperial College; 2006. 
31. Liang F, Romanienko PJ, Weaver DT, Jeggo PA, Jasin M: Chromo-
somal double-strand break repair in Ku80-deficient cells.
Proc Natl Acad Sci U S A 1996, 93(17):8929-8933.
32. Yun S, Lie ACC, Porter AC: Discriminatory suppression of
homologous recombination by p53.  Nucleic Acids Res 2004,
32(22):6479-6489.
33. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H:
Transcriptional activation by tetracyclines in mammalian
cells.  Science 1995, 268(5218):1766-1769.
34. Freundlieb S, Schirra-Muller C, Bujard H: A tetracycline control-
led activation/repression system with increased potential for
gene transfer into mammalian cells.  J Gene Med 1999,
1(1):4-12.
35. Rossi FM, Guicherit OM, Spicher A, Kringstein AM, Fatyol K, Blakely
BT, Blau HM: Tetracycline-regulatable factors with distinct
dimerization domains allow reversible growth inhibition by
p16.  Nat Genet 1998, 20(4):389-393.
36. Gallia GL, Khalili K: Evaluation of an autoregulatory tetracy-
cline regulated system.  Oncogene 1998, 16(14):1879-1884.
37. Gould DJ, Berenstein M, Dreja H, Ledda F, Podhajcer OL, Chernajo-
vsky Y: A novel doxycycline inducible autoregulatory plasmid
which displays "on"/"off" regulation suited to gene therapy
applications.  Gene Ther 2000, 7(24):2061-2070.
38. Hofmann A, Nolan GP, Blau HM: Rapid retroviral delivery of tet-
racycline-inducible genes in a single autoregulatory cassette.
Proc Natl Acad Sci U S A 1996, 93(11):5185-5190.
39. Kuhnel F, Fritsch C, Krause S, Mundt B, Wirth T, Paul Y, Malek NP,
Zender L, Manns MP, Kubicka S: Doxycycline regulation in a sin-
gle retroviral vector by an autoregulatory loop facilitates
controlled gene expression in liver cells.  Nucleic Acids Res 2004,
32(3):e30.
40. Markusic D, Oude-Elferink R, Das AT, Berkhout B, Seppen J: Com-
parison of single regulated lentiviral vectors with rtTA
expression driven by an autoregulatory loop or a constitu-
tive promoter.  Nucleic Acids Res 2005, 33(6):e63.
41. O'Brien K, Otto K, Rao RN: Construction and characterization
of a one-plasmid system for the controlled expression of
genes in mammalian cells by tetracycline.  Gene 1997,
184(1):115-120.
42. S AM, Hawkins RE: Efficient transgene regulation from a single
tetracycline-controlled positive feedback regulatory system.
Gene Ther 1998, 5(1):76-84.
43. Shockett P, Difilippantonio M, Hellman N, Schatz DG: A modified
tetracycline-regulated system provides autoregulatory,
inducible gene expression in cultured cells and transgenic
mice.  Proc Natl Acad Sci U S A 1995, 92(14):6522-6526.
44. Strathdee CA, McLeod MR, Hall JR: Efficient control of tetracy-
cline-responsive gene expression from an autoregulated bi-
directional expression vector.  Gene 1999, 229(1-2):21-29.
45. Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze
MT:  Second-generation tetracycline-regulatable promoter:
repositioned tet operator elements optimize transactivator
synergy while shorter minimal promoter offers tight basal
leakiness.  J Gene Med 2004, 6(7):817-828.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Molecular Biology 2007, 8:30 http://www.biomedcentral.com/1471-2199/8/30
Page 14 of 14
(page number not for citation purposes)
46. Backman CM, Zhang Y, Hoffer BJ, Tomac AC: Tetracycline-induc-
ible expression systems for the generation of transgenic ani-
mals: a comparison of various inducible systems carried in a
single vector.  J Neurosci Methods 2004, 139(2):257-262.
47. Gould DJ, Chernajovsky Y: Endogenous GATA factors bind the
core sequence of the tetO and influence gene regulation
with the tetracycline system.  Mol Ther 2004, 10(1):127-138.
48. Rang A, Will H: The tetracycline-responsive promoter con-
tains functional interferon-inducible response elements.
Nucleic Acids Res 2000, 28(5):1120-1125.
49. Iida A, Chen ST, Friedmann T, Yee JK: Inducible gene expression
by retrovirus-mediated transfer of a modified tetracycline-
regulated system.  J Virol 1996, 70(9):6054-6059.
50. Kamper MR, Gohla G, Schluter G: A novel positive tetracycline-
dependent transactivator (rtTA) variant with reduced back-
ground activity and enhanced activation potential.  FEBS Lett
2002, 517(1-3):115-120.
51. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W:
Exploring the sequence space for tetracycline-dependent
transcriptional activators: novel mutations yield expanded
range and sensitivity.  Proc Natl Acad Sci U S A 2000,
97(14):7963-7968.
52. Wells KD, Foster JA, Moore K, Pursel VG, Wall RJ: Codon optimi-
zation, genetic insulation, and an rtTA reporter improve
performance of the tetracycline switch.  Transgenic Res 1999,
8(5):371-381.
53. Hefferin ML, Tomkinson AE: Mechanism of DNA double-strand
break repair by non-homologous end joining.  DNA Repair
(Amst) 2005, 4(6):639-648.
54. Clark AJ, Harold G, Yull FE: Mammalian cDNA and prokaryotic
reporter sequences silence adjacent transgenes in trans-
genic mice.  Nucleic Acids Res 1997, 25(5):1009-1014.
55. Scrable H, Stambrook PJ: A genetic program for deletion of for-
eign DNA from the mammalian genome.  Mutat Res 1999,
429(2):225-237.
56. Suzuki M, Kasai K, Saeki Y: Plasmid DNA sequences present in
conventional herpes simplex virus amplicon vectors cause
rapid transgene silencing by forming inactive chromatin.  J
Virol 2006, 80(7):3293-3300.
57. Kolb AF, Ansell R, McWhir J, Siddell SG: Insertion of a foreign
gene into the beta-casein locus by Cre-mediated site-specific
recombination.  Gene 1999, 227(1):21-31.
58. Shmerling D, Danzer CP, Mao X, Boisclair J, Haffner M, Lemaistre M,
Schuler V, Kaeslin E, Korn R, Burki K, Ledermann B, Kinzel B, Muller
M: Strong and ubiquitous expression of transgenes targeted
into the beta-actin locus by Cre/lox cassette replacement.
Genesis 2005, 42(4):229-235.
59. Wutz A, Rasmussen TP, Jaenisch R: Chromosomal silencing and
localization are mediated by different domains of Xist RNA.
Nat Genet 2002, 30(2):167-174.
60. Puttini S, Ouvrard-Pascaud A, Palais G, Beggah AT, Gascard P, Cohen-
Tannoudji M, Babinet C, Blot-Chabaud M, Jaisser F: Development
of a targeted transgenesis strategy in highly differentiated
cells: a powerful tool for functional genomic analysis.  J Bio-
technol 2005, 116(2):145-151.
61. Itzhaki JE, Porter AC: Targeted disruption of a human inter-
feron-inducible gene detected by secretion of human growth
hormone.  Nucleic Acids Res 1991, 19(14):3835-3842.
62. Johnson RD, Liu N, Jasin M: Mammalian XRCC2 promotes the
repair of DNA double-strand breaks by homologous recom-
bination.  Nature 1999, 401(6751):397-399.
63. Itzhaki JE, Gilbert CS, Porter AC: Construction by gene targeting
in human cells of a "conditional' CDC2 mutant that rerepli-
cates its DNA.  Nat Genet 1997, 15(3):258-265.
64. Yanez RJ, Porter AC: Gene targeting is enhanced in human
cells overexpressing hRAD51.  Gene Ther 1999, 6(7):1282-1290.
65. Yanez RJ, Porter AC: Differential effects of Rad52p overexpres-
sion on gene targeting and extrachromosomal homologous
recombination in a human cell line.  Nucleic Acids Res 2002,
30(3):740-748.